NeuroVigil

NeuroVigil specializes in developing advanced neurotechnology, primarily focusing on brain activity monitoring through its innovative iBrain device, which aids in diagnosing neurological disorders. NeuroVigil, founded in the US, is dedicated to pioneering neurotechnology solutions. The company has not undergone any significant pivots but operates as an independent entity. The founder's background is not specified.

As of May 1, 2015, NeuroVigil raised USD 0. 25 mn in a Seed round led by Draper Fisher Jurvetson, Frontier Venture Capital, and Zone Ventures, marking a total amount raised of USD 0. 25 mn across three deals. Neurovigil, Inc.

specializes in advanced neurotechnology, primarily through its flagship product, the iBrain, a portable device designed to monitor brain activity using a single-electrode electroencephalogram (EEG) cap. The iBrain enables users to record brainwave data during sleep, facilitating the early diagnosis of neurological disorders such as Alzheimer's, Parkinson's, and sleep apnea. By employing the SPEARS (Sleep Parametric EEG Automated Recognition System Algorithm), this technology allows for real-time analysis of brain activity, significantly enhancing traditional research methodologies in neuroscience and psychopharmacology. Neurovigil's target clientele includes pharmaceutical companies and research institutions involved in the development of CNS (central nervous system) therapies, primarily focusing on markets in North America and Europe.

The company aims to provide innovative solutions for individuals suffering from neurological conditions, ensuring that the technology remains accessible without invasive procedures. Neurovigil's revenue model is centered on partnerships with pharmaceutical companies and research institutions that utilize its iBrain technology in clinical trials and research initiatives. Transactions typically occur on a subscription basis, where clients engage Neurovigil for a specified period, gaining access to the iBrain devices and analysis services for their studies. These arrangements often include comprehensive support services that ensure effective integration of the technology into existing research frameworks.

The revenue structure is designed to facilitate ongoing collaborations, emphasizing long-term relationships with clients committed to advancing neurological research. By providing neurodiagnostic tools and services, Neurovigil positions itself as a pivotal player in the neurotechnology industry, driving innovation and improving outcomes in the healthcare sector. NeuroVigil plans to leverage the recent Seed round funding from May 2015 to enhance product development and support its expansion efforts. The company is currently working on new iterations of the iBrain device and anticipates launching these advancements in the near future.

Additionally, it aims to expand its market reach into Europe and Asia by 2025, targeting pharmaceutical companies and research institutions that focus on central nervous system disorders.